ContraFect Corporation (CFRX) Shares Down 12.5%
Shares of ContraFect Corporation (NASDAQ:CFRX) were down 12.5% during mid-day trading on Friday . The company traded as low as $0.80 and last traded at $0.88. Approximately 607,596 shares traded hands during trading, an increase of 554% from the average daily volume of 92,903 shares. The stock had previously closed at $1.00.
Separately, Maxim Group reaffirmed a “hold” rating on shares of ContraFect Corporation in a research report on Thursday, May 25th.
The company has a 50-day moving average price of $1.19 and a 200-day moving average price of $1.52. The stock’s market capitalization is $64.45 million.
ContraFect Corporation (NASDAQ:CFRX) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.11. Analysts anticipate that ContraFect Corporation will post ($0.43) EPS for the current fiscal year.
In related news, Director Sol J. Barer acquired 40,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was acquired at an average price of $1.24 per share, with a total value of $49,600.00. Following the completion of the transaction, the director now owns 815,933 shares of the company’s stock, valued at $1,011,756.92. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought 50,800 shares of company stock valued at $62,992 in the last ninety days. 9.30% of the stock is owned by company insiders.
A hedge fund recently bought a new stake in ContraFect Corporation stock. Westfield Capital Management Co. LP acquired a new stake in shares of ContraFect Corporation (NASDAQ:CFRX) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 149,600 shares of the biotechnology company’s stock, valued at approximately $269,000. Westfield Capital Management Co. LP owned about 0.36% of ContraFect Corporation as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 24.45% of the company’s stock.
About ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.